Please note, this OEL/ADE monograph also applies to metamizole sodium (CAS RN 68-89-3; 5907-38-0), metamizole calcium (CAS RN 51996-59-9), metamizole quinine (CAS RN 97259-64-8), and metamizole magnesium hexahydrate (CAS RN 667459-72-5). Metamizole is a pyrazolone derivative that belongs to the group of nonacid nonopioids. The metamizole sodium salt, also known as dipyrone, has the powerful analgesic and antipyretic effect. Because of the risk of serious adverse effects, in many countries, its use is considered justified only in severe pain or fever where no alternative is available or suitable. It was withdrawn from many markets in the 1970s due to a risk of causing agranulocytosis.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Metamizole, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.